Edwards Lifesciences Corp (EW)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $61.61B
Last updated: Nov 17, 2026 at 11:06 AM ET
Edwards Lifesciences Corp (EW) Stock Forecast
Analysts expect Edwards Lifesciences (EW) to earn $3.01 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.81B. Of 30 analysts, 23 rate the stock Buy or Strong Buy, 7 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 30 ratings average 2.07, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 77% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 16.7% |
| Buy | 18 | 60.0% |
| Hold | 7 | 23.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 30
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 12.6% and revenue estimates rise 9.8%.
- Fiscal year ending Dec 31, 2026
- $3.01
- EPS consensus, revenue $6.81B
- Fiscal year ending Dec 31, 2027
- $3.39
- EPS consensus, revenue $7.48B
- Next report
- Feb 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.01 | $2.97 to $3.05 | 29 | $6.81B | $6.72B to $6.86B | 27 |
| Dec 31, 2027 | $3.39 | $2.99 to $3.49 | 29 | $7.48B | $7.26B to $7.71B | 28 |
Quarterly Estimates
The EPS consensus rises from $0.69 for the quarter ending Dec 31, 2026 to $0.84 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.69 | $0.63 to $0.79 | 28 | $1.76B | $1.66B to $1.88B | 29 |
| Mar 31, 2027 | $0.84 | $0.77 to $0.90 | 19 | $1.80B | $1.77B to $1.84B | 18 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 6 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 3 | 5 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.3% from $3.00.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $3.01 | $3.00 | $3.00 | $3.00 | $3.00 | +0.5% |
| Fiscal year ending Dec 31, 2027 | $3.39 | $3.38 | $3.38 | $3.38 | $3.38 | +0.3% |
| Quarter ending Mar 31, 2027 | $0.84 | $0.83 | $0.83 | $0.83 | $0.83 | +1.2% |
Frequently Asked Questions About EW
What is the EW stock forecast?
Consensus analyst estimates put Edwards Lifesciences's EPS at $3.01 for the fiscal year ending Dec 31, 2026, on revenue of $6.81B. The consensus rating from 30 analysts is Buy.
How do analysts rate EW stock?
Of 30 analysts covering Edwards Lifesciences, 5 rate it Strong Buy, 18 Buy, 7 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from EW next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.01, with estimates from $2.97 to $3.05 from 29 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.39, with estimates from $2.99 to $3.49 from 29 analysts.
What revenue do analysts expect from Edwards Lifesciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.81B, with estimates from $6.72B to $6.86B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $7.48B, with estimates from $7.26B to $7.71B.
How many analysts cover EW?
30 analysts rate Edwards Lifesciences stock, and 29 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
EW pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts